No title
Background The estrogen receptor alpha (ERa), encoded by ESR1, is overexpressed in 75 – 80 % of breast cancers. Treatments targeting ERa are challenged by development of resistance due to loss of ERa expression. It is crucial to increase understanding of regulatory mechanisms of ERa expression and identify alterations in these mechanisms. Modifications of miRNA target sites in ESR1 3’ UTR or meth
